Dina Turner

Co-founder & CEO @Gameto

Austin, TX, US

Gameto is a biotechnology company using cell engineering to develop therapeutics for diseases of the female reproductive system. Our first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective by shortening injections from 2 weeks to 2-3 days. Fertilo has received numerous regulatory approvals, babies have been born with the technology, numerous pregnancies and is now in final phase 3 trial for US approval. Beyond fertility, our ovaroid iPSC-derived platform developed in collaboration with Professor George Church’s lab at Harvard Medical School yields a pipeline of products in women’s and reproductive health including menopause/primary ovarian insufficiency treatment. Gameto has raised $127M in funding to date from investors including Overwater Ventures, Two Sigma Ventures, RA Capital, Insight Partners, Future Ventures, Bold Capital, Lux Capital, Bob Nelsen of Arch Ventures, and Anne Wojcicki of 23andMe, and $10 million from ARPA-H Sprint for Women’s Health to accelerate the company’s menopause program.

UCL

Bachelor’s Degree, iBSc Physiology

UCL

Bachelor of Medicine, Bachelor of Surgery (M.B.B.S.)

Anglo-American School

High School